ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Veterinary Imaging
This article is part of the Research TopicRecent Advances in the Management of Cardiac Disease in Companion AnimalsView all 8 articles
Early Detection of Subclinical Heart Disease via Nonlinear Heart Rate Variability in a doxorubicin-Induced Cardiomyopathy Experimental Model in Dogs
Provisionally accepted- 1Tokyo University of Agriculture and Technology, Fuchu, Japan
- 2College of Veterinary Medicine University of Florida, Florida, United States
- 3Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan
- 4Juntendo University, Urayasu Hospital, Urayasu, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Echocardiography is the first choice for assessing the structure and function of the heart, but it is unclear for detecting subclinical changes. In recent years, abnormal heart rate variability (HRV) has received attention for its ability to identify patients at risk for developing heart failure. HRV analysis in veterinary medicine is predominantly limited to linear analysis, which primarily reflects advanced heart disease. In contrast, nonlinear HRV analysis holds the potential for early detection of heart disease, but its quantitative evaluation remains rare. Objectives: This study aimed to evaluate the feasibility of using HRV for the early heart disease detection in clinical settings, with a focus on doxorubicin (DXR)-induced myocardial damage in dogs. Animals and Methods: Six healthy female dogs with no abnormalities on physical examination, blood pressure, electrocardiography (ECG) and echocardiography were selected in this study. The dogs had an average age of 1.2 years and an average body weight of 8.1 kg. After recording blood pressure, ECG and echocardiography, the dogs were fitted with a Holter ECG, and measurements were taken for 2 days. Following the removal of the Holter ECG, DXR at 30 mg/m2 was administered over 30 minutes, repeated every 3 weeks, up to a maximum cumulative dose of 180 mg/m2. Each measurement was taken before the first and after the final DXR dose. Results: There were no changes in recommended parameters of left ventricular systolic function (FS: 34.4 % [33.9 - 42.8] vs. 37.8 % [34.7 - 42.8], p = 0.73, GLS EN: -19.1 % [-21.3 - -17.5] vs. -18.0 % [- 19.3 - -17.3], p = 0.68). However, the Poincaré plot of nonlinear HRV significantly reflected increased sympathetic activity (SD1/SD2: 0.58 % [0.57 - 0.60 vs. 0.42 % [0.40 - 0.45], p = 0.008, SD2/SD1: 1.8 % [1.76 - 1.82] vs. 2.5 % [2.3 - 2.7], p = 0.008). Conclusions: The finding that nonlinear HRV analysis reflected early increased sympathetic activity associated with DXR administration in dogs is an important step forward in enhancing the clinical application potential of HRV.
Keywords: Cardiology, Dogs, Holterelectrocardiography, Parasympatheticnerves, Poincaréplot, Sympatheticnerves, Two-dimensional speckle-tracking echocardiography
Received: 15 Oct 2025; Accepted: 15 Dec 2025.
Copyright: © 2025 Hasegawa, Sasaki, Umemoto, Hayashi, Hatanaka, Hosoki, Farag, Hamabe, Shimada, Matsuura, Yoshida, Takahashi and Tanaka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ryou Tanaka
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
